Last reviewed · How we verify
adjuvanted FLU-v
At a glance
| Generic name | adjuvanted FLU-v |
|---|---|
| Sponsor | PepTcell Limited |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women (PHASE2)
- A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine (PHASE2)
- Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model (PHASE2)
- Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen (NA)
- Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults (PHASE2)
- Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older (PHASE3)
- Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59 (PHASE1)
- A Study to Assess Immunogenicity Parameters After Vaccination Against Influenza and to Evaluate How These Parameters Change During the Influenza Season (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |